Tag: umbilical cord

Boca Raton, Florida, June 27, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it has entered into securities purchase agreements with two healthcare focused institutional investors for the purchase and sale of 3,000,000 shares of its common stock in a registered direct offering (the "Offering") at a purchase price of $6.30 per share, priced at-the-market under Nasdaq rules.

MIAMI, June 06, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced that it will present the rationale and study design of its Phase 2/3 IIMPACT (Idiopathic Inflammatory Myopathy Phase 2/3 Adaptive Clinical Trial) trial of Restem-L, the Company’s umbilical-lining modified progenitor cells (UMPC) program for the treatment of Polymyositis and Dermatomyositis (PM/DM), a rare autoimmune disease, now defined by the FDA as Idiopathic Inflammatory Myopathy (IIM). The oral presentation will be delivered at the European Alliance of Associations for Rheumatology's (EULAR) 2025 Congress, to take place June 11-14 in Barcelona, Spain.